Ad
related to: keytruda lung cancer side effects- Learn About SCLC
Get Facts About SCLC & Learn About
A Treatment Option.
- How the Treatment Works
Learn How a SCLC Treatment Option
Works & See If It's Right for You.
- Downloadable Brochure
Download the Patient Brochure &
Learn More About a SCLC Treatment.
- Dosing Info for Patients
Find Official Dosing Info & Related
Info for a SCLC Treatment Option.
- Learn About SCLC
Search results
Results from the WOW.Com Content Network
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 Inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. [12] [14] [15] [16] It is administered by slow intravenous ...
Pembrolizumab (Keytruda, formerly MK-3475 and lambrolizumab) was developed by Merck and first approved by the Food and Drug Administration in 2014 for the treatment of melanoma. It was later approved for metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. In 2017, it became the first immunotherapy drug approved for ...
It was approved in 2014. Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. [16] Pembrolizumab (brand name Keytruda) is another PD-1 inhibitor that was approved by the FDA in 2014 and was the second checkpoint inhibitor approved in the United States. [17]
Merck is discontinuing the Phase 3 KEYNOTE-867 trial evaluating Keytruda (pembrolizumab) in combination with stereotactic body radiotherapy (SBRT) for stage I or II non-small cell lung cancer ...
A trial of the drug in patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma was stopped for "futility", meaning it was likely to fail, the company said.
Nearly a quarter of patients who received Merck & Co's immunotherapy Keytruda as an initial treatment for advanced lung cancer were still alive after five years, according to data presented at a ...
The trial evaluating Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with Lynparza (olaparib), with or without bevacizumab, as a first-line treatment for BRCA non-mutated ...
Other side effects of cisplatin include nausea and vomiting which usually necessitate premedication with antiemetic medications before infusion; ear damage (ototoxicity), which could manifest in varying levels of hearing loss; peripheral neuropathy; and bone marrow suppression (myelosuppression). [16] Carboplatin
Ad
related to: keytruda lung cancer side effects